SYRS Quote, Financials, Valuation and Earnings

Biogen has a net margin of -- compared to Syros Pharmaceuticals's net margin of 15.76%. Syros Pharmaceuticals's return on equity of -- beat Biogen's return on equity of 10.52%.

Syros Pharmaceuticals has a consensus price target of --, signalling upside risk potential of 387.33%. On the other hand Biogen has an analysts' consensus of $242.83 which suggests that it could grow by 65.79%. Given that Syros Pharmaceuticals has higher upside potential than Biogen, analysts believe Syros Pharmaceuticals is more attractive than Biogen.

Syros Pharmaceuticals has a beta of 1.329, which suggesting that the stock is 32.939% more volatile than S&P 500. In comparison Biogen has a beta of -0.081, suggesting its less volatile than the S&P 500 by 108.074%.

Syros Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Biogen offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Syros Pharmaceuticals pays -- of its earnings as a dividend. Biogen pays out -- of its earnings as a dividend.

Syros Pharmaceuticals quarterly revenues are --, which are smaller than Biogen quarterly revenues of $2.5B. Syros Pharmaceuticals's net income of -$6.4M is lower than Biogen's net income of $388.5M. Notably, Syros Pharmaceuticals's price-to-earnings ratio is -- while Biogen's PE ratio is 13.23x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Syros Pharmaceuticals is 0.76x versus 2.23x for Biogen. Usually stocks with elevated PS ratios are considered overvalued.

iBio has a net margin of -- compared to Syros Pharmaceuticals's net margin of -4444.57%. Syros Pharmaceuticals's return on equity of -- beat iBio's return on equity of -148.3%.

Syros Pharmaceuticals has a consensus price target of --, signalling upside risk potential of 387.33%. On the other hand iBio has an analysts' consensus of -- which suggests that it could grow by 45.16%. Given that Syros Pharmaceuticals has higher upside potential than iBio, analysts believe Syros Pharmaceuticals is more attractive than iBio.

Syros Pharmaceuticals has a beta of 1.329, which suggesting that the stock is 32.939% more volatile than S&P 500. In comparison iBio has a beta of -3.237, suggesting its less volatile than the S&P 500 by 423.713%.

Syros Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. iBio offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Syros Pharmaceuticals pays -- of its earnings as a dividend. iBio pays out -- of its earnings as a dividend.

Syros Pharmaceuticals quarterly revenues are --, which are smaller than iBio quarterly revenues of $175K. Syros Pharmaceuticals's net income of -$6.4M is lower than iBio's net income of -$4M. Notably, Syros Pharmaceuticals's price-to-earnings ratio is -- while iBio's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Syros Pharmaceuticals is 0.76x versus -- for iBio. Usually stocks with elevated PS ratios are considered overvalued.

NovaBay Pharmaceuticals has a net margin of -- compared to Syros Pharmaceuticals's net margin of -49.65%. Syros Pharmaceuticals's return on equity of -- beat NovaBay Pharmaceuticals's return on equity of -461.38%.

Syros Pharmaceuticals has a consensus price target of --, signalling upside risk potential of 387.33%. On the other hand NovaBay Pharmaceuticals has an analysts' consensus of -- which suggests that it could grow by 602.96%. Given that NovaBay Pharmaceuticals has higher upside potential than Syros Pharmaceuticals, analysts believe NovaBay Pharmaceuticals is more attractive than Syros Pharmaceuticals.

Syros Pharmaceuticals has a beta of 1.329, which suggesting that the stock is 32.939% more volatile than S&P 500. In comparison NovaBay Pharmaceuticals has a beta of 0.686, suggesting its less volatile than the S&P 500 by 31.383%.

Syros Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Syros Pharmaceuticals pays -- of its earnings as a dividend. NovaBay Pharmaceuticals pays out -- of its earnings as a dividend.

Syros Pharmaceuticals quarterly revenues are --, which are smaller than NovaBay Pharmaceuticals quarterly revenues of $2.4M. Syros Pharmaceuticals's net income of -$6.4M is lower than NovaBay Pharmaceuticals's net income of -$1.2M. Notably, Syros Pharmaceuticals's price-to-earnings ratio is -- while NovaBay Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Syros Pharmaceuticals is 0.76x versus 0.06x for NovaBay Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

Palatin Technologies has a net margin of -- compared to Syros Pharmaceuticals's net margin of -2357.27%. Syros Pharmaceuticals's return on equity of -- beat Palatin Technologies's return on equity of --.

Syros Pharmaceuticals has a consensus price target of --, signalling upside risk potential of 387.33%. On the other hand Palatin Technologies has an analysts' consensus of -- which suggests that it could grow by 1656.38%. Given that Palatin Technologies has higher upside potential than Syros Pharmaceuticals, analysts believe Palatin Technologies is more attractive than Syros Pharmaceuticals.

Syros Pharmaceuticals has a beta of 1.329, which suggesting that the stock is 32.939% more volatile than S&P 500. In comparison Palatin Technologies has a beta of 0.901, suggesting its less volatile than the S&P 500 by 9.9%.

Syros Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Palatin Technologies offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Syros Pharmaceuticals pays -- of its earnings as a dividend. Palatin Technologies pays out -- of its earnings as a dividend.

Syros Pharmaceuticals quarterly revenues are --, which are smaller than Palatin Technologies quarterly revenues of $350K. Syros Pharmaceuticals's net income of -$6.4M is higher than Palatin Technologies's net income of -$7.8M. Notably, Syros Pharmaceuticals's price-to-earnings ratio is -- while Palatin Technologies's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Syros Pharmaceuticals is 0.76x versus -- for Palatin Technologies. Usually stocks with elevated PS ratios are considered overvalued.